Fig. 1From: Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancerSankey Chart for Number (%) of Patients Receiving First- and Second-Line Treatment. Note: Only cabozantinib and vandetanib were approved by the US Food and Drug Administration for the treatment of advanced medullary thyroid cancer at the time of the studyBack to article page